Skip to main content
. Author manuscript; available in PMC: 2022 Jun 7.
Published in final edited form as: Ann Oncol. 2022 Jan 21;33(4):426–433. doi: 10.1016/j.annonc.2022.01.006

Figure 2. Variant allele fraction (VAF) of pathogenic/likely pathogenic (P/LP) germline variants and overall detection of germline variants as per biological process and tumor type.

Figure 2.

(A) Tumor VAF of the P/LP germline variants technically detected by tumor-only sequencing per cancer susceptibility gene (CSG). (B and C) Proportion of P/LP germline variants not detected by tumor-only sequencing either by technical detection or by a VAF lower than the recommended thresholds according to (B) biological process and (C) tumor type.

HRD, homologous recombination deficiency; DDR, DNA damage response; MMR, mismatch repair; SNV, single-nucleotide variant.